Ovarian epithelial cancer

Common Name(s)

Ovarian epithelial cancer

Ovarian cancer, the leading cause of death from gynecologic malignancy, is characterized by advanced presentation with loco-regional dissemination in the peritoneal cavity and the rare incidence of visceral metastases ({6:Chi et al., 2001}). These typical features relate to the biology of the disease, which is a principal determinant of outcome ({1:Auersperg et al., 2001}). Epithelial ovarian cancer is the most common form and encompasses 5 major histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Epithelial ovarian cancer arises as a result of genetic alterations sustained by the ovarian surface epithelium ({44:Stany et al., 2008}; {43:Soslow, 2008}).
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Ovarian epithelial cancer" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Ovarian epithelial cancer" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Ovarian epithelial cancer" returned 684 free, full-text research articles on human participants. First 3 results:

Overexpression of FOXM1 predicts poor prognosis and promotes cancer cell proliferation, migration and invasion in epithelial ovarian cancer.
 

Author(s): Ning Wen, Yu Wang, Li Wen, Shu-Hua Zhao, Zhen-Hua Ai, Yi Wang, Bo Wu, Huai-Xiu Lu, Hong Yang, Wen-Chao Liu, Yu Li

Journal:

 

The Forkhead box M1 (FOXM1), an important regulator of cell differentiation and proliferation, is overexpressed in a number of aggressive human carcinomas. The purpose of this study was to examine the expression levels of FOXM1 in epithelial ovarian cancer (EOC), to identify the relationship ...

Last Updated: 20 Jun 2014

Go To URL
Recurrence season impacts the survival of epithelial ovarian cancer patients.
 

Author(s): Xiao-Hui Liu, Ya-Nan Man, Xiong-Zhi Wu

Journal: Asian Pac. J. Cancer Prev.. 2014 ;15(4):1627-32.

 

Several studies indicated that the diagnosis season affects the prognosis of some cancers, such as examples in the prostate, colon and breast This retrospective study aimed to investigate whether the diagnosis and recurrent season impacts the prognosis of epithelial ovarian cancer patients.

Last Updated: 19 Mar 2014

Go To URL
A phase II study of paclitaxel and carboplatin with a biweekly schedule in patients with epithelial ovarian cancer: Gynecologic Cancer Network trial.
 

Author(s): Koichi Yoneyama, Hideki Konishi, Tetsuro Yahata, Kazuyuki Fujita, Yoichi Aoki, Daisuke Doi, Takashi Matsushima, Shoji Kodama, Shigeru Honma, Hisamori Kato, Hiroki Nakayama, Seiryu Kamoi, Hirobumi Asakura, Toshiyuki Takeshita, Kenichi Tanaka

Journal: J Nippon Med Sch. 2014 ;81(1):28-34.

 

The objective of this multicenter phase II study was to evaluate the effects of biweekly paclitaxel and carboplatin combination chemotherapy on response rate and toxicities in patients with epithelial ovarian cancer.

Last Updated: 11 Mar 2014

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Ovarian epithelial cancer" returned 62 free, full-text review articles on human participants. First 3 results:

The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis.
 

Author(s): Chaoyang Sun, Na Li, Dong Ding, Danhui Weng, Li Meng, Gang Chen, Ding Ma

Journal:

 

The role of BRCA dysfunction on the prognosis of patients with epithelial ovarian cancer (EOCs) remains controversial. This systematic review tried to assess the role of BRCA dysfunction, including BRCA1/2 germline, somatic mutations, low BRCA1 protein/mRNA expression or BRCA1 promoter ...

Last Updated: 5 May 2014

Go To URL
Chemokine receptors in epithelial ovarian cancer.
 

Author(s): Goda G Muralidhar, Maria V Barbolina

Journal:

 

Ovarian carcinoma is the deadliest gynecologic malignancy with very poor rate of survival, and it is characterized by the presence of vast incurable peritoneal metastasis. Studies of the role of chemokine receptors, a family of proteins belonging to the group of G protein-coupled ...

Last Updated: 3 Jan 2014

Go To URL
Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease.
 

Author(s): B J Monk, E Pujade-Lauraine, R A Burger

Journal: Ann. Oncol.. 2013 Dec;24 Suppl 10():x53-x58.

 

Angiogenesis plays a fundamental role in the pathogenesis of ovarian cancer. Vascular endothelial growth factor (VEGF) expression has been associated with the development of malignant ascites and tumor progression. Bevacizumab (Avastin(®); Genentech, South San Francisco, CA, USA), ...

Last Updated: 22 Nov 2013

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma
 

Status: Recruiting

Condition Summary: Ovarian Neoplasms; Ovarian Epithelial Cancer

 

Last Updated: 12 May 2014

Go to URL
Vaccine Therapy in Treating Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Following Surgery and Chemotherapy
 

Status: Recruiting

Condition Summary: Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mixed Epithelial Carcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Undifferentiated Adenocarcinoma; Recurrent Fallopian Tube Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Primary Peritoneal Cavity Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Epithelial Cancer; Stage IIIC Primary Peritoneal Cavity Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Primary Peritoneal Cavity Cancer

 

Last Updated: 15 Dec 2014

Go to URL
Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma
 

Status: Recruiting

Condition Summary: Ovarian Neoplasms; Ovarian Cancer (OvCa); Ovarian Epithelial Cancer

 

Last Updated: 12 May 2014

Go to URL